Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma

Laura L. Hoang, David Tacha, Ryan E. Bremer, Thomas S. Haas, Liang Cheng

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Distinguishing between invasive urothelial carcinoma from other genitourinary lesions such as prostatic and renal carcinomas can be difficult, and may require highly sensitive immunohistochemical markers. GATA-binding protein 3 (GATA3) has been reported in a high percentage of urothelial and breast carcinomas. Mouse monoclonal uroplakin II (UPII) and p40 antibodies have recently been developed and demonstrated high specificity in urothelial carcinoma. This study evaluated the immunohistochemical staining sensitivities of UPII, GATA3, p40, and p63 in the detection of invasive urothelial carcinoma. UPII, GATA3, and p40 were further tested for specificity in lung, breast, colon, kidney, and prostate cancers. In all invasive urothelial carcinoma cases, UPII, GATA3, p40, and p63 exhibited sensitivities of 77.7%, 83.5%, 85.4%, and 80.6%, respectively. The combination of UPII, GATA3, and p40 antibodies stained 94.2% (97/103) of all invasive urothelial carcinoma cases, including 92.2% (71/77) of grade 2-3 urothelial carcinomas. In addition, GATA3 and UPII showed negative staining in lung squamous cell carcinomas and p40 showed negative staining in breast infiltrating ductal carcinomas. The combination of UPII, GATA3, and p40 showed negative staining in lung adenocarcinoma, colon adenocarcinoma, and renal carcinomas. In conclusion, UPII, GATA3, and p40, when used in combination, are highly sensitive in the differential diagnosis of invasive urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)711-716
Number of pages6
JournalApplied Immunohistochemistry and Molecular Morphology
Volume23
Issue number10
StatePublished - 2015

Fingerprint

Uroplakin II
Carrier Proteins
Differential Diagnosis
Carcinoma
Negative Staining
Breast Neoplasms
Carcinoma, Ductal, Breast
adjuvant P40
Antibodies
Kidney Neoplasms
Renal Cell Carcinoma
Colonic Neoplasms
Squamous Cell Carcinoma
Lung Neoplasms
Prostatic Neoplasms

Keywords

  • GATA3
  • p40
  • Uroplakin II
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology

Cite this

Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma. / Hoang, Laura L.; Tacha, David; Bremer, Ryan E.; Haas, Thomas S.; Cheng, Liang.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 23, No. 10, 2015, p. 711-716.

Research output: Contribution to journalArticle

@article{83ddedf94f8241518ffb08b87db3a92f,
title = "Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma",
abstract = "Distinguishing between invasive urothelial carcinoma from other genitourinary lesions such as prostatic and renal carcinomas can be difficult, and may require highly sensitive immunohistochemical markers. GATA-binding protein 3 (GATA3) has been reported in a high percentage of urothelial and breast carcinomas. Mouse monoclonal uroplakin II (UPII) and p40 antibodies have recently been developed and demonstrated high specificity in urothelial carcinoma. This study evaluated the immunohistochemical staining sensitivities of UPII, GATA3, p40, and p63 in the detection of invasive urothelial carcinoma. UPII, GATA3, and p40 were further tested for specificity in lung, breast, colon, kidney, and prostate cancers. In all invasive urothelial carcinoma cases, UPII, GATA3, p40, and p63 exhibited sensitivities of 77.7{\%}, 83.5{\%}, 85.4{\%}, and 80.6{\%}, respectively. The combination of UPII, GATA3, and p40 antibodies stained 94.2{\%} (97/103) of all invasive urothelial carcinoma cases, including 92.2{\%} (71/77) of grade 2-3 urothelial carcinomas. In addition, GATA3 and UPII showed negative staining in lung squamous cell carcinomas and p40 showed negative staining in breast infiltrating ductal carcinomas. The combination of UPII, GATA3, and p40 showed negative staining in lung adenocarcinoma, colon adenocarcinoma, and renal carcinomas. In conclusion, UPII, GATA3, and p40, when used in combination, are highly sensitive in the differential diagnosis of invasive urothelial carcinoma.",
keywords = "GATA3, p40, Uroplakin II, Urothelial carcinoma",
author = "Hoang, {Laura L.} and David Tacha and Bremer, {Ryan E.} and Haas, {Thomas S.} and Liang Cheng",
year = "2015",
language = "English (US)",
volume = "23",
pages = "711--716",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma

AU - Hoang, Laura L.

AU - Tacha, David

AU - Bremer, Ryan E.

AU - Haas, Thomas S.

AU - Cheng, Liang

PY - 2015

Y1 - 2015

N2 - Distinguishing between invasive urothelial carcinoma from other genitourinary lesions such as prostatic and renal carcinomas can be difficult, and may require highly sensitive immunohistochemical markers. GATA-binding protein 3 (GATA3) has been reported in a high percentage of urothelial and breast carcinomas. Mouse monoclonal uroplakin II (UPII) and p40 antibodies have recently been developed and demonstrated high specificity in urothelial carcinoma. This study evaluated the immunohistochemical staining sensitivities of UPII, GATA3, p40, and p63 in the detection of invasive urothelial carcinoma. UPII, GATA3, and p40 were further tested for specificity in lung, breast, colon, kidney, and prostate cancers. In all invasive urothelial carcinoma cases, UPII, GATA3, p40, and p63 exhibited sensitivities of 77.7%, 83.5%, 85.4%, and 80.6%, respectively. The combination of UPII, GATA3, and p40 antibodies stained 94.2% (97/103) of all invasive urothelial carcinoma cases, including 92.2% (71/77) of grade 2-3 urothelial carcinomas. In addition, GATA3 and UPII showed negative staining in lung squamous cell carcinomas and p40 showed negative staining in breast infiltrating ductal carcinomas. The combination of UPII, GATA3, and p40 showed negative staining in lung adenocarcinoma, colon adenocarcinoma, and renal carcinomas. In conclusion, UPII, GATA3, and p40, when used in combination, are highly sensitive in the differential diagnosis of invasive urothelial carcinoma.

AB - Distinguishing between invasive urothelial carcinoma from other genitourinary lesions such as prostatic and renal carcinomas can be difficult, and may require highly sensitive immunohistochemical markers. GATA-binding protein 3 (GATA3) has been reported in a high percentage of urothelial and breast carcinomas. Mouse monoclonal uroplakin II (UPII) and p40 antibodies have recently been developed and demonstrated high specificity in urothelial carcinoma. This study evaluated the immunohistochemical staining sensitivities of UPII, GATA3, p40, and p63 in the detection of invasive urothelial carcinoma. UPII, GATA3, and p40 were further tested for specificity in lung, breast, colon, kidney, and prostate cancers. In all invasive urothelial carcinoma cases, UPII, GATA3, p40, and p63 exhibited sensitivities of 77.7%, 83.5%, 85.4%, and 80.6%, respectively. The combination of UPII, GATA3, and p40 antibodies stained 94.2% (97/103) of all invasive urothelial carcinoma cases, including 92.2% (71/77) of grade 2-3 urothelial carcinomas. In addition, GATA3 and UPII showed negative staining in lung squamous cell carcinomas and p40 showed negative staining in breast infiltrating ductal carcinomas. The combination of UPII, GATA3, and p40 showed negative staining in lung adenocarcinoma, colon adenocarcinoma, and renal carcinomas. In conclusion, UPII, GATA3, and p40, when used in combination, are highly sensitive in the differential diagnosis of invasive urothelial carcinoma.

KW - GATA3

KW - p40

KW - Uroplakin II

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84947254559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947254559&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 711

EP - 716

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 10

ER -